Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as "Dragon Sail Pharmaceutical") formally signed a strategic cooperation agreement in Guilin, southern of China. This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC). Attendees at the signing ceremony included Mr. Ju Nianfeng, Chairman and General Manager of Porton Pharma Solutions, Mr. Zou Xun, Chairman of Guilin Sanjin, and Mr. Tan Kai, General Manager of Dragon Sail Pharmaceutical.

As a leading end-to-end integrated CDMO company in the industry, Porton Pharma Solutions boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling), and Advanced Therapy Medicinal Products. Dragon Sail Pharmaceutical, on the other hand, has unique advantages in the development of biological drugs such as monoclonal antibodies, bispecific antibodies, and fusion proteins. By integrating resources, technical capabilities, and production capacities in the ADC drug field, the two companies will leverage supply chain resource sharing and complementary strengths to form a close cooperation mechanism. This partnership aims to establish a comprehensive one-stop service platform for ADC drugs, encompassing the entire process from bulk drug substances to finished products, from early-stage development to commercial production. By doing so, the collaboration seeks to shorten ADC drug development timelines, enhance service and delivery capabilities, and improve market competitiveness, providing global customers with more efficient and reliable one-stop CMC solutions for ADC drugs.

At the ceremony, Mr. Oliver (Nianfeng) Ju, Chairman and CEO of Porton Pharma Solutions, stated, "This strategic cooperation is of great significance, not only helping enhance the competitiveness of both businesses but also bringing more innovative achievements to the pharmaceutical industry. Moving forward, Porton will continue to leverage its ADC drug platform advantages, deepen cooperation with Dragon Sail Pharmaceutical, and work together to contribute to the advancement of the global pharmaceutical industry."

At the ceremony, Mr. Zou Xun, Chairman of Guilin Sanjin, remarked, "This partnership goes beyond deep business integration between the two companies; it is also aimed at promoting the development of ADC drugs."

Looking ahead, Porton Pharma Solutions and Dragon Sail Pharmaceutical will take Shanghai Waigaoqiao (Porton) and Shanghai Lingang (White Sail) as their bases to uphold the shared vision of enabling the public's early access to good medicines together, they will strive to create a globally impactful and sustainable pharmaceutical ecosystem through technological innovation and business model innovation. By completing resource integration and improving overall efficiency, the two companies aim to jointly promote the rapid and healthy development of the global ADC pharmaceutical industry.